Connor, Clark & Lunn Investment Management Ltd. Unity Biotechnology, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$0.4 - $4.27 $64,817 - $691,923	162,043 New	162,043 $64,000
Q2 2022 Aug 05, 2022	SELL	$0.56 - $1.29 $18,993 - $43,752	-33,917 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.72 - $1.86 $43,462 - $112,278	-60,365 Reduced 64.03%	33,917 $38,000
Q4 2021 Feb 10, 2022	BUY	$1.3 - $3.17 $122,566 - $298,873	94,282 New	94,282 $138,000

Others Institutions Holding UBX

# of Institutions

Shares Held

4.41M

Call Options Held

Put Options Held

Empery Asset Management, LP New York, NY

4.41M
Shares

$5.07 Million
10.37% of portfolio

View Full List

About Unity Biotechnology, Inc.

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $16.1M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

More about UBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account